Impact of chronic lung allograft dysfunction, especially restrictive allograft syndrome, on the survival after living-donor lobar lung transplantation compared with cadaveric lung transplantation in adults: a single-center experience by Sugimoto, Seiichiro et al.
Sugimoto et al. 
 
 1 
Original Article (Clinical Original) 1 
 2 
Impact of chronic lung allograft dysfunction, especially restrictive allograft 3 
syndrome, on the survival after living-donor lobar lung transplantation compared 4 
with cadaveric lung transplantation in adults: A single-center experience 5 
 6 
Seiichiro Sugimoto 1, Haruchika Yamamoto 1, Takeshi Kurosaki 2, Shinji Otani 2,  7 
Mikio Okazaki 1, Masaomi Yamane 1, Shinichi Toyooka 1, Takahiro Oto 2 8 
 9 
1 Department of General Thoracic Surgery, Okayama University Hospital, Japan 10 
2 Department of Organ Transplant Center, Okayama University Hospital, Japan 11 
 12 
Correspondence:  13 
Seiichiro Sugimoto, MD, PhD 14 
Department of General Thoracic Surgery, Okayama University Hospital, 2-5-1 Shikata-15 
cho, Kita-ku, Okayama 700-8558, Japan  16 
 E-mail: sugimo-s@cc.okayama-17 u.ac.jp
 18 




Purpose: The differences in chronic lung allograft dysfunction (CLAD) between living-2 
donor lobar lung transplantation (LDLLT) and cadaveric lung transplantation (CLT) remain 3 
unclear. We conducted this study to compare the impact of CLAD on the outcomes after 4 
LDLLT vs. CLT. 5 
Methods: We conducted a retrospective review of the data of 97 recipients of bilateral 6 
lung transplantation, including 51 recipients of LDLLT and 46 recipients of CLT. 7 
Results: The CLAD-free survival and overall survival after LDLLT were similar to those 8 
after CLT. CLAD and restrictive allograft syndrome (RAS), but not bronchiolitis obliterans 9 
syndrome (BOS), developed significantly later after LDLLT than after CLT (p = 0.015 and 10 
p = 0.035). Consequently, patients with CLAD and RAS, but not those with BOS, after 11 
LDLLT had a significantly better overall survival than those after CLT (p = 0.037 and p = 12 
0.0006). Furthermore, after the diagnosis of CLAD, the survival of patients with RAS after 13 
LDLLT tended to be better than that after CLT (p = 0.083). 14 
Conclusion: CLAD, especially RAS, appears to develop later after LDLLT than after CLT 15 
and seems to have a lower impact on the overall survival after LDLLT than that after CLT. 16 
 17 
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Living-donor lobar lung transplantation (LDLLT) has become an established treatment for 2 
end-stage lung diseases [1-3] and has been shown to result in a similar survival to 3 
cadaveric lung transplantation (CLT) [3]. Similar to the case after CLT, chronic lung 4 
allograft dysfunction (CLAD) is a major obstacle hampering the long-term survival after 5 
LDLLT [2, 3].  6 
In bilateral LDLLT, because the right and left lower lobes of the lungs from two 7 
different donors are implanted in the recipient in place of the entire lungs, the different 8 
immunological features between the two donor lungs may affect the characteristics of 9 
CLAD after LDLLT. Indeed, CLAD has been shown to develop predominantly on one side 10 
after bilateral LDLLT [4]. Furthermore, morphologically, size mismatch between the chest 11 
cavity of the recipient and the donor lobar lungs might also affect the development of 12 
CLAD after LDLLT [5]. It was shown more than a decade ago that the rate of freedom 13 
from bronchiolitis obliterans syndrome (BOS) did not differ markedly between LDLLT and 14 
CLT [6]; however, since the introduction of the concept of restrictive allograft syndrome 15 
(RAS) [7], little information has been obtained regarding the differences in the phenotypes 16 
of CLAD between LDLLT and CLT, especially in relation to the long-term outcomes of 17 
CLAD.  18 
In the present study, we compared the impact of CLAD on the long-term outcomes 19 
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This study was a retrospective review of patients who underwent bilateral lung 1 
transplantation (LT) for end-stage lung disease at Okayama University Hospital between 2 
October 1998 and August 2016. Patients undergoing lung retransplantation and patients 3 
<18 years of age were excluded from this study in order to eliminate the effect of the initial 4 
LT and the effect of physical growth on the lung function in pediatric patients. A total of 97 5 
adult patients who underwent bilateral LT, including 51 recipients of bilateral LDLLT and 6 
46 recipients of bilateral CLT, were included in this study. One patient underwent bilateral 7 
LDLLT sparing the native right upper lobe. We assessed the preoperative and operative 8 
patient characteristics and the postoperative outcomes. The lung allocation score (LAS) 9 
of each patient was retrospectively calculated using the LAS calculator published on the 10 
OPTN website (https://optn.transplant.hrsa.gov/resources/allocation-calculators/las-11 
calculator/) in November 2015 in order to establish the recipients’ preoperative disease 12 
severity. The CLAD-free survival was defined as the interval from LT to the onset of CLAD, 13 
and the data were censored on the date of death. The overall survival was defined as the 14 
interval from LT to the date of death.  15 
The study protocol (No. 1803-008) was approved by the institutional review board 16 
of Okayama University Hospital.  17 
 18 
Donor and recipient selection and the transplantation procedures 19 
Patients requiring CLT are registered with the Japan Organ Transplantation Network. The 20 
allocation of organs from brain-dead donors is still based mainly on the waiting time, and 21 
the LAS system has not yet been adopted in Japan. LDLLT is considered for critically ill 22 
patients who cannot afford to wait for CLT. Patients hoping for LDLLT must meet all if the 23 
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criteria for CLT. Only blood relatives within the third degree or a spouse are accepted as 1 
living donors at our institution. The size-matching protocol and transplant procedures 2 
have been described in a previous report [8]. The graft ischemic time was defined as the 3 
ischemic time to the second transplanted lung.  4 
 5 
Postoperative care 6 
The postoperative management of the recipients, including the immunosuppressive 7 
therapy and prescribed prophylactic therapies against fungal and viral infections, has 8 
been described elsewhere [9, 10]. The patients were assigned PGD grades according to 9 
the definition of primary graft dysfunction proposed by the International Society for Heart 10 
and Lung Transplantation (ISHLT) [11]. LT recipients received triple immunosuppressive 11 
therapy consisting of tacrolimus or cyclosporine, mycophenolate mofetil or azathioprine, 12 
and a corticosteroid. The calcineurin inhibitor was initially given by the enteric route via a 13 
nasogastric tube during the first period between 1998 and 2010 and by intravenous 14 
administration during the second period between 2011 and 2017, followed by oral 15 
administration [10]. Acute rejection episodes were treated by bolus intravenous 16 
corticosteroid therapy on three consecutive days. Pulmonary function testing, including 17 
measurement of the forced expiratory volume in 1 second (FEV1) to diagnose BOS 18 
(obstructive CLAD) [12] and that of the total lung capacity (TLC) to diagnose RAS 19 
(restrictive CLAD) [7], was performed at 3, 6, and 12 months and once every year 20 
thereafter following LT. According to the classification system proposed by the ISHLT [12], 21 
the baseline FEV1 value was calculated as the average of the two best FEV1 values 22 
obtained at least three weeks apart, and the baseline values of other parameters of 23 
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pulmonary function test were taken as the average of the parameters measured at the 1 
time of the best FEV1 measurements. CLAD was defined as an irreversible decline in 2 
FEV1 to <80% of the baseline [12]. RAS was defined as CLAD with an irreversible decline 3 
in TLC to <90% of the baseline [7]. BOS was defined as CLAD without restrictive changes 4 
of RAS [7]. For a definitive diagnosis of CLAD, blood examinations, chest X-ray, computed 5 
tomography of the chest, inspiratory and expiratory computed tomography volumetry, 6 
ventilation-perfusion scanning, and electrocardiography were also performed at the same 7 
time as the pulmonary function testing. Among these, computed tomography of the chest, 8 
inspiratory and expiratory computed tomography volumetry, and ventilation-perfusion 9 
scanning were mainly used to exclude other potential causes of a reduced lung function 10 
[4, 7, 12, 13]. The six-minute walk test and echocardiography were performed at the same 11 
time during the first five years after LT. 12 
 13 
Statistical analyses 14 
All statistical analyses were performed using the GraphPad Prism 7.03 software program 15 
(San Diego, CA, USA). Normally distributed continuous data were expressed as the 16 
means ± standard deviations. The bivariate comparison of continuous variables was 17 
performed by Student’s t-test. Associations between categorical variables were examined 18 
by Fisher’s exact test. The postoperative survival rates were analyzed by the Kaplan–19 
Meier method, and the log rank test was used to compare the differences between the 20 
groups. Differences were considered significant at p <0.05. The results as of October 31, 21 
2017, were analyzed. 22 
 23 




Patient characteristics 2 
Table 1 summarizes the patients’ characteristics. The proportion of female patients was 3 
significantly higher in the LDLLT group than in the CLT group (p = 0.0007). The LAS of 4 
the LDLLT group was significantly higher than that of the CLT group (p < 0.0001). In regard 5 
to the donor variables, the donor age was significantly lower in the LDLLT group than in 6 
the CLT group (p < 0.0001). While the total number of HLA-A, HLA-B, and HLA-DR 7 
mismatches with the bilateral donors in the LDLLT group was significantly higher than that 8 
in the CLT group (p < 0.0001), those of the right lung lobe donor or left lung lobe donor 9 
alone in the LDLLT group were significantly lower than in the CLT group (p < 0.0001). The 10 
total ischemic time in the LDLLT group was significantly shorter than that in the CLT group 11 
(p < 0.0001). Furthermore, the highest grade of PGD until 72 h after the LT in the LDLLT 12 
group was significantly lower than that in the CLT group (p < 0.0001). 13 
 14 
Outcomes of CLAD 15 
The CLAD-free survival after LDLLT was similar to that after CLT (p = 0.57) (Fig. 1), as 16 
were the BOS- and RAS-free survival. In the LDLLT group, CLAD developed 17 
predominantly in the lung of one side at disease onset in 19 of 22 patients, including 10 18 
patients with BOS and 9 patients with RAS. The time of onset of CLAD in the LDLLT group 19 
was significantly later than that in the CLT group (p = 0.015) (Fig. 2a). With regard to the 20 
CLAD phenotypes, while the time of the onset of BOS was similar between the two groups, 21 
the onset of RAS in the LDLLT group occurred significantly later than that in the CLT group 22 
(p = 0.035) (Fig. 2b, c). One patient in the LDLLT group, who first developed the BOS 23 
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phenotype and thereafter the RAS phenotype, was treated for BOS according to the 1 
CLAD onset type. There was no significant difference in the overall survival after LT 2 
between the 2 groups (p = 0.11) (Fig. 3). However, patients who developed CLAD after 3 
LDLLT showed a significantly better overall survival than those who developed CLAD 4 
after CLT (p = 0.037) (Fig. 4a). Furthermore, while the overall survival of patients who 5 
developed BOS after LT was similar between the two groups, patients who developed 6 
RAS after LDLLT showed a significantly better overall survival than those who developed 7 
RAS after CLT (p = 0.0006) (Fig. 4b, c). There were no significant differences in the 8 
survival after the diagnosis of CLAD between the two LT groups; however, the survival of 9 
patients who developed RAS after LDLLT tended to be better than that of patients who 10 
developed RAS after CLT (p = 0.083) (Fig. 5a, b, c). 11 
 12 
Discussion 13 
Although the donor characteristics and the recipient characteristics were different 14 
between LDLLT and CLT, the CLAD-free survival and overall survival after bilateral LT 15 
were similar between the recipients of LDLLT and CLT. However, CLAD, especially RAS, 16 
but not BOS, after LDLLT, developed at a later time than that after CLT. Owing to the later 17 
development of CLAD or RAS after LDLLT, the recipients with CLAD or RAS after LDLLT 18 
showed a favorable overall survival compared to the recipients who developed CLAD or 19 
RAS after CLT. Furthermore, following the diagnosis of CLAD, the survival of patients who 20 
developed RAS after LDLLT tended to be better than that of patients who developed RAS 21 
after CLT. Our results suggest that CLAD after LDLLT may have a similar incidence but 22 
develop at a later time compared with CLAD occurring after CLT; in addition, CLAD 23 
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developing after LDLLT has a lower impact on the overall survival than that developing 1 
after CLT. 2 
The differences in the characteristics of the donors and recipients reflected the 3 
differences in the procedures between LDLLT and CLT. First, LDLLT is usually performed 4 
in small adult females or pediatric patients; thus, the proportion of female recipients in the 5 
LDLLT group was significantly higher than that in the CLT group. The survival of adult 6 
primary LT recipients has been reported to be significantly better among females than 7 
among males [14]; however, the overall survival did not differ markedly between the two 8 
groups. In addition, to eliminate the influence of the effect of physical growth on the lung 9 
function in pediatric patients, pediatric patients were excluded from this study. Second, 10 
the preoperative severity of the disease, which was reflected by the LAS, was significantly 11 
greater in the LDLLT recipients than in the CLT recipients, because LDLLT is the main 12 
option for urgent LT in Japan due to the severe shortage of donor organs. As LT has been 13 
shown to provide a survival benefit even for high-LAS patients if lungs are transplanted 14 
from a low-risk donor [15], the overall survival after LDLLT was comparable to that after 15 
CLT. Third, the mean age of the healthy living donors for LDLLT was significantly lower 16 
than that of the deceased donors for CLT, and the quality of the donor lungs, as 17 
represented by the lung donor score, was significantly better in the LDLLT group than in 18 
the CLT group. Consequently, despite the smaller size of the pulmonary vascular bed in 19 
the lobar grafts, ideal grafts were implanted with a shorter ischemic time in LDLLT, which 20 
resulted in less severe PGD after LDLLT than after CLT. Because the severity of PGD has 21 
been shown to be associated with the risk of CLAD [16], the less severe PGD after LDLLT 22 
than after CLT may have contributed to the delayed development of CLAD after LDLLT 23 
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observed in this study. 1 
Although LDLLT provided a similar CLAD-free survival to CLT in this study, CLAD, 2 
especially RAS, developed significantly later after LDLLT than after CLT. The delayed 3 
development of RAS after LDLLT may be attributed to the morphological characteristics 4 
in LDLLT. After LDLLT, small lobar grafts gradually expand to fit the recipient’s chest cavity 5 
due to the size mismatch, leading to gradual improvement of the pulmonary function 6 
parameters, especially the forced vital capacity, during the first two years after LDLLT [17]. 7 
This expansion of the lobar lungs during the first two years after LDLLT may contribute to 8 
the delayed development of RAS after LDLLT. Furthermore, CLAD developed 9 
predominantly unilaterally at the disease onset after bilateral LDLLT in this study, 10 
consistent with a previously report [4]. Because LDLLT involves 2 different donors for 11 
each recipient and the total number of HLA mismatches can be up to 12, the total number 12 
of HLA mismatches with the bilateral donors of the LDLLT group was significantly higher 13 
than with the donors of the CLT group; however, the total number of HLA mismatches with 14 
the unilateral donors alone of the LDLLT group was significantly lower than that with the 15 
donors of the CLT group. We therefore speculated that immunological similarity between 16 
the donor lungs from blood relatives and the recipients in LDLLT might contribute to the 17 
delayed development of CLAD after LDLLT [18]. 18 
The development of CLAD unilaterally after LDLLT appeared not to be related to 19 
the delayed development of CLAD after LDLLT in this study. Because CLAD developed 20 
unilaterally after bilateral LDLLT, the unaffected contralateral lung might mask the decline 21 
in the pulmonary function and delay the diagnosis of CLAD after LDLLT [4]. However, 22 
consistent with the results of a previous report [4], the decline in the pulmonary function 23 
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occurred at the same time as the diagnosis of CLAD by ventilation scintigraphy, which 1 
has been shown to be more useful for the early detection of CLAD after LT than computed 2 
tomography [19]. 3 
Regarding the survival after LT, the delayed development of CLAD and RAS, but 4 
not BOS, contributed to the better overall survival in the patients who developed CLAD 5 
after LDLLT than in those who developed CLAD after CLT. In CLT, oversized allografts 6 
have been shown to be associated with a less frequent occurrence of BOS [5] and an 7 
increased survival after LT [20]. However, in LDLLT, undersized donor grafts have been 8 
shown to expand more after LDLLT than oversized donor grafts [21]. Because smaller 9 
grafts were implanted in LDLLT than in CLT, as shown by the size matching in this study, 10 
such mismatch might affect the outcomes after LDLLT, similar to those after CLT. Further 11 
examinations will be required to investigate the association between size matching and 12 
CLAD or the survival after LDLLT. However, once the recipients were diagnosed with 13 
CLAD, the impact of CLAD developing after LDLLT on the survival after the disease onset 14 
did not markedly differ from that of CLAD developing after CLT. Thus, lung transplant 15 
physicians should be aware of the characteristics associated with the delayed 16 
development of CLAD after LDLLT for appropriate long-term management, such as drug 17 
dose reduction and withdrawal in maintenance immunosuppression, except for recipients 18 
of LDLLT from the same donor as that for the hematopoietic stem cell transplantation. 19 
Our study had several limitations. First, this was a retrospective observational study 20 
conducted at a single transplant center. Second, although the follow-up period was more 21 
than one year in all patients in this study, this period was still intermediate in some cases, 22 
and longer follow-up periods will be required for further validation of the prognostic impact 23 
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of CLAD. Third, the follow-up period was significantly different between the two groups, 1 
and CLAD after CLT was shown to develop later in the long-term follow-up than that after 2 
LDLLT. Finally, the number of LT recipients was small, because in addition to the exclusion 3 
of pediatric patients, patients who underwent single LT were also excluded from this study 4 
in order to eliminate the effect of the native contralateral lungs on the lung function. 5 
However, considering that LDLLT is currently performed exclusively in Japan, our study 6 
provides pertinent information about the differences in the prognostic impact of CLAD 7 
developing after LDLLT versus that developing after CLT. 8 
In conclusion, the CLAD-free survival after LDLLT was similar to that after CLT, 9 
similar to findings for the overall survival after LT. However, CLAD, especially RAS, 10 
developed at a later time after LDLLT than after CLT, leading to a better overall survival 11 
of patients with CLAD and RAS in the LDLLT group than in the CLT group.  12 
 13 
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Figure legends 1 
Fig. 1. The CLAD-free survival after living-donor lobar lung transplantation (LDLLT) and 2 
cadaveric lung transplantation (CLT). The CLAD-free survival rates were similar between 3 
the recipients of LDLLT and those of CLT (5-year CLAD-free survival rate, 74.5% vs. 4 
65.7%; 10-year CLAD-free survival rate, 59.6% vs. 65.7%) (p = 0.79). 5 
 6 
Fig. 2. The interval from lung transplantation to the diagnosis of chronic lung allograft 7 
dysfunction (CLAD) after living-donor lobar lung transplantation (LDLLT) and cadaveric 8 
lung transplantation (CLT). (a) The CLAD onset occurred significantly later in the LDLLT 9 
group than in the CLT group (1807 ± 1402 vs. 689 ± 584 days, p = 0.015). (b) The timing 10 
of the onset of bronchiolitis obliterans syndrome (BOS) did not differ markedly between 11 
the two groups (1360 ± 1319 vs. 595 ± 643 days, p = 0.19). (c) The timing of the onset of 12 
RAS in the LDLLT group was significantly later than in the CLT group (2343 ± 1307 vs. 13 
820 ± 460 days, p = 0.035).  14 
  15 
Fig. 3. The overall survival after living-donor lobar lung transplantation (LDLLT) and 16 
cadaveric lung transplantation (CLT). There was no significant difference in the overall 17 
survival rates between recipients of LDLLT and those of CLT (5-year survival rate, 82.0% 18 
vs. 69.6%; 10-year survival rate, 72.7% vs. 55.7%) (p = 0.10).  19 
 20 
Fig. 4. The overall survival of patients with chronic lung allograft dysfunction (CLAD) after 21 
living-donor lobar lung transplantation (LDLLT) and cadaveric lung transplantation (CLT). 22 
(a) The overall survival rates of the patients developing CLAD after LDLLT were 23 
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significantly better than those of the patients developing CLAD after CLT (5-year survival 1 
rate, 72.4% vs. 50.0%) (p = 0.037). (b) The survival of the patients who developed BOS 2 
after LT was similar between the 2 groups (p = 0.90). (c) Patients developing RAS after 3 
LDLLT had a significantly better survival than those who developed RAS after CLT (p = 4 
0.0006). 5 
 6 
Fig. 5. The survival after the diagnosis of chronic lung allograft dysfunction (CLAD) after 7 
living-donor lobar lung transplantation (LDLLT) and cadaveric lung transplantation (CLT). 8 
There was no significant difference in the survival after disease onset among patients 9 
who developed CLAD (p = 0.57) (a), BOS (p = 0.49) (b), and RAS (c) (p = 0.083).10 
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Number of patients 51 46
Age, years 37.5 ± 11.6 37.6 ± 12.9 0.98
Gender, female 44 (86.3%) 25 (54.3%) 0.0007
Diagnoses
Interstitial lung disease 21 (41.2%) 11 (23.9%) 0.086
Pulmonary hypertension 11 (21.6%) 13 (28.3%) 0.49
Pulmonary GVHD 7 (13.7%) 5 (10.9%) 0.76
Lymphangioleiomyomatosis 4 (7.8%) 5 (10.9%) 0.73
Bronchiectasis 3 (5.9%) 7 (15.2%) 0.18
Other diseases 5 (9.8%) 5 (10.9%) > 0.99
Preoperative steroid use 24 (47.1%) 18 (39.1%) 0.54
Body mass index 17.9 ± 4.0 19.5 ± 4.7 0.071
Lung allocation score 50.6 ± 15.2 39.0 ± 6.5 < 0.0001
Donor variables
Donor age 38.5 ± 11.5 47.8 ± 12.7 < 0.0001
Donor gender, female 48 (47.1%) 19 (41.3%) 0.59
4 (7.8%) 6 (0.13%) 0.51
63.0 ± 12.1 99.5 ± 16.0 < 0.0001
Bilateral donors 6.4 ± 2.1 4.8 ± 0.8 < 0.0001
Right lung donor 3.3 ± 1.4 4.8 ± 0.8 < 0.0001
Left lung donor 3.1 ± 1.3 4.8 ± 0.8 < 0.0001
Total ischemic time (min) 163.2 ± 35.4 549.9 ± 112.7 < 0.0001
Cardiopulmonary bypass use 51 (100.0%) 45 (97.8%) 0.47
3 (5.9%) 6 (13.0%) 0.30
Primary graft dysfunction grade 0.9 ± 1.0 1.9 ± 1.2 < 0.0001
Acute rejection, number
First period 1.5 ± 1.1 1.0 ± 1.1 0.21
Second period 0.3 ± 0.7 0.2 ± 0.5 0.53
30-day mortality 1 (2.0%) 2 (4.4%) 0.60
Postoperative GERD 2 (3.9%) 0 0.50
CLAD 22 (43.1%) 12 (26.1%) 0.09
BOS 12 (23.5%) 7 (15.2%) 0.44
RAS 10 (19.6%) 5 (10.9%) 0.27
3514 ± 1984 1601 ± 1057 < 0.0001
Postoperative ECMO




BOS, bronchiolitis obliterans syndrome; CLAD, chronic lung allograft dysfunction; ECMO, extracorporeal
membrane oxygenation; FVC, forced vital capacity; GERD, gastroesophageal reflux disease; GVHD, graft-
versus-host disease; HLA, human leucocyte antigen; PGD, primary graft dysfunction; RAS, restrictive
allograft syndrome
FVC-based size matching (%)
Time since transplant to follow-up
(days)
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